Radioligand binding to adenosine receptors and adenosine uptake sites in different brain regions of normal and narcoleptic dogs.
The present study compares the characteristics of radioligand binding to adenosine receptors and adenosine uptake sites in 100- and 50-day-old normal and narcoleptic dogs. Binding to A1 receptors was quantified using a selective A1 agonist ([3H]N6-[(R)-1-methyl-2-phenylethyl] adenosine, [3H]R-PIA) and an antagonist ([3H]dipropyl-8-cyclopentyl-xanthine, [3H]CPX). Differences in the binding of [3H]R-PIA and that of [3H]5'-ethylcarboxamide adenosine ([3H]NECA), which binds to both A1 and A2 receptors with similar affinities, were used to quantify A2 receptors. Nucleoside transport sites were labeled with [3H]nitrobenzylthioinosine ([3H]NBTI), a potent inhibitor of nucleoside transport systems. The present study offered no evidence that either adenosine A1 receptors and adenosine uptake sites in the frontal cortex or adenosine A2 receptors in the putamen were altered in narcoleptic dogs. However, we found that adenosine A1 receptors in the dog exist in different affinity states and that the affinity state in which the receptor is found depends on the brain region examined. A characterization of these low- and high-affinity sites was performed and results indicated that these sites cannot be explained by a single interaction of the A1 receptor with a single G-protein population.
Hawkins
M
M
Department of Pharmacology, University of Illinois, College of Medicine, Chicago.
O'Connor
S
S
Radulovacki
M
M
Bowersox
S
S
Mignot
E
E
Dement
W
W
D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism*; D019830:Adenosine-5'-(N-ethylcarboxamide); D000375:Aging / Q000502:physiology; D000818:Animals; D001921:Brain / Q000378:metabolism*; D002385:Cataplexy / Q000139:chemically induced / Q000503:physiopathology; D004285:Dogs; D019204:GTP-Binding Proteins / Q000378:metabolism; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D007700:Kinetics; D008566:Membranes / Q000378:metabolism; D009290:Narcolepsy / Q000378:metabolism*; D010660:Phenylisopropyladenosine / Q000378:metabolism; D011869:Radioligand Assay; D011983:Receptors, Purinergic / Q000378:metabolism*; D013868:Thioinosine / Q000031:analogs & derivatives / Q000378:metabolism; D014970:Xanthines / Q000378:metabolism
D011983:Receptors, Purinergic; D014970:Xanthines; D010660:Phenylisopropyladenosine; D006165:Guanylyl Imidodiphosphate; D019830:Adenosine-5'-(N-ethylcarboxamide); D013868:Thioinosine; C051360:1,3-dipropyl-8-cyclopentylxanthine; D019204:GTP-Binding Proteins; C001789:4-nitrobenzylthioinosine; D000241:Adenosine